A Phase 2 Study of REGN2810 a Fully Human Monoclonal Antibody to Programmed Death-1 in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor therapy
Brief description of study
If you have been diagnosed with advanced metastatic (cancer spreading to other areas within the body) basal cell carcinoma or unresectable advanced basal cell carcinoma and experienced disease progression while on hedgehog inhibitor (HHI) therapy; you may qualify to participate in a study evaluating how effective REGN2810 (an anti-PD-1 monoclonal antibody) is effective at preventing further progression of your disease. This study will also evaluate the safety and tolerability of REGN2810 in your body, as well as the immune system's response to the drug.
Clinical Study Identifier: s17-00080
ClinicalTrials.gov Identifier: NCTs17-00080
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
